To include your compound in the COVID-19 Resource Center, submit it here.

HemoShear, Takeda in liver disease deal

HemoShear Therapeutics LLC (Charlottesville, Va.) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH). HemoShear will receive

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE